Synthesis and primary cytotoxicity evaluation of new 5-bromo-3-substituted-hydrazono-1H-2-indolinones

Archiv der Pharmazie

Volumn 335, Issue 8, 2002, Pages 374-380

  Karali, Nilgün ^a   Terzioǧlu, Nalan ^a   Gürsoy, Aysel ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

2 Thioxo 4,5 imidazolidinediones; 5 Bromo 1H 2 indolinones; 5 Methyl 4 thiazolidinones; Cytotoxicity

Indexed keywords

2 THIOXO 4,5 IMIDAZOLIDINEDIONE DERIVATIVE; 4 FLUOROPHENYLTHIOSEMICARBAZONE DERIVATIVE; 5 BROMO 1H 2 INDOLINONE DERIVATIVE; 5 METHYL 4 THIAZOLIDINONE DERIVATIVE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE; CHEMISTRY, PHYSICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDICATORS AND REAGENTS; INDOLES; MASS SPECTROMETRY; SPECTROPHOTOMETRY, INFRARED; TUMOR CELLS, CULTURED;

EID: 0036806068     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4184(200211)335:8<374::AID-ARDP374>3.0.CO;2-K     Document Type: Article

References (24)

1. D. Maysinger, J. Ban, M. Movrin, Arzeniem.-Forsch./Drug Res. 1980, 30, 932-935.
2. N. H. Eshba, H. M. Salama, I. M. Labouta, A.-M. M. E. Omar, Pharmazie 1987, 10, 664-666.
3. M. A. Badawy, S. A. Abdelsady, Arch. Pharm. (Weinheim) 1991, 324, 349-351.
4. Y. Teitz, N. Barko, M. Abramoff, D. Ronen, Chemotherapy 1994, 40, 195-200.
5. Y. Teitz, D. Ronen, A. Vansover, T. Stematsky, J. L. Riggs, Antiviral Res. 1994, 24, 305-314.
6. J. Winter, R. L. Hall, R. W. Moyer, Virology 1995, 211 462-473.
7. M. L. Sethi, Principles of Medicinal Chemistry, (Eds.: W. O. Foye, T. L. Lemke, D. A. Wiliams), Williams and Wilkins, Baltimore, 1995, 845-861.
8. Z. Juranic, F. Anatasova, I. Juranic, T. Stanojkovic, S. Radulovic, N. Vuletic, J. Exp. Clin. Cancer Res. 1999, 18, 317-324.
9. N. H. Eshba, H. M. Salama, Pharmazie 1985, 40, 320-322.
10. N. Karali, A. Gürsoy, Farmaco 1994, 49, 819-822.
11. I. Petrov. O. Grupce, T. Stafilov, J. Mol. Struct. 1986, 142, 275-278.
12. P. Naumov, F. Anastasova, Spectr. Acta, 2001, 57A, 469-481.
13. M. A. Moustafa, S. M. Bayomi, A. A. El-Emam, M. M. El- Kerdawy, Sci. Pharm. 1989, 57, 125-130.
14. S. Özkirimli, Pharmazie 1993, 48, 10.
15. A.-M. M. E. Omar, N. H. Eshba, H. M. Salama, Arch. Pharm. (Weinheim) 1984, 317, 701-709.
16. A. M. Farghaly, N. S. Habib, M. A. Khalil, O. A. El-Sayed, A. E. Bistawroos, Arch. Pharm. (Weinheim) 1990, 323, 247-251.
17. H. Laatsch, R. H.Thomson, P. J. Cox, J. Chem. Soc. Perkin Trans. II 1984, 1331-1340.
18. M. L. Baron, L. L. Martin, I. D. Era, P. M. Simmonds, M. L. Woolcock, Aust. J. Chem. 1990, 43, 741-747.
19. R. S. Varma, A. P. Singh, S. P. Singh, Org. Mass Spectr. 1992, 27, 17-18.
20. L. Somogyi, Tetrahedron 1985, 41, 5187-5190.
21. J. R. Dimmrock, S. A. Patil, M. S. Sardessai, M. Mazurek, Pharmazie 1987, 42, 111-113.
22. M. C. Alley, D. A. Scudiero, P. A. Monks, M. L. Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbott, J. G. Mayo, R. H. Shoemaker, M. R. Boyd, Cancer Research 1988, 48, 589-601.
23. M. R. Grever, S. A. Schepartz, B. A. Chabner, Cancer Drug Discovery and Development Program. Seminars in Oncology 1992, 19, 622-638.
24. M. R. Boyd, K. D. Paull, Drug Devel. Res. 1995, 34, 91- 109.